Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AdvaMed Lobbying Costs 40% Less in 3Q of 2010

January 4, 2011 6:23 am | News | Comments

The medical device industry's chief advocacy group spent over $358,000 lobbying the federal government in the third quarter of 2010, according to a recent disclosure form.


Allergan Spent $250,000 Lobbying in the 3Q

January 4, 2011 6:19 am | News | Comments

Specialty drugmaker Allergan Inc., which makes eye care products and Botox anti-wrinkle injections, spent $250,000 lobbying in the third quarter, according to a federal filing.


New Therapeutic Target for Hepatitis C

January 4, 2011 6:15 am | News | Comments

Scientists have identified a molecular interaction between a structural hepatitis C virus protein and a protein critical to viral replication. This new finding strongly suggests a novel method of inhibiting the production of the virus.


NC Doubles Medicaid Unit Budget

January 4, 2011 6:03 am | News | Comments

Attorney General Roy Cooper is getting extra help to investigate Medicaid fraud in North Carolina after a successful year recovering funds from those accused of cheating the government medical program for the poor.


Third Quarter Lobbying Runs Lilly $2.1M

January 4, 2011 6:01 am | News | Comments

Drug maker Eli Lilly and Co. punched up its spending on federal lobbying in the third quarter as it focused on market access and pricing reform in Europe, trade issues and the healthcare overhaul, among other matters.


J & J Lobbying Up 40% Over 2009

January 4, 2011 5:59 am | News | Comments

Johnson & Johnson, the maker of health products from baby shampoo to birth control pills, spent $2.4 million in the third quarter to lobby on legislation affecting its medicines, medical devices and other business interests.


Abbott Lobbying Costs Up $140K

January 4, 2011 5:56 am | News | Comments

Drug and medical device maker Abbott Laboratories spent $910,000 in the third quarter to lobby the federal government on policies affecting its products. The company's spending was up from $650,000 in the second quarter and $770,000 in the prior-year period.


Automated Assay Washing

January 3, 2011 7:01 am | Product Releases | Comments

Tecan’s HydroFlex microplate washer has allowed hematologists at the University of Modena to introduce automated washing for Enzyme-Linked ImmunoSpot (ELISpot) assays.


Pharmaceutical Virtualization

January 3, 2011 6:54 am | Product Releases | Comments

Fluid Air announces the release of a white paper detailing the advantages of the use of virtual machines in pharmaceutical process control software.


Longevinex Shows L-Shaped Safety Curve

January 3, 2011 6:40 am | News | Comments

While it is possible to drink too much wine or ingest too much resveratrol, in an unprecedented study, heart researchers report they couldn't find a toxic dose for Longevinex, a resveratrol-based dietary supplement.


Cystic Fibrosis Protein Also Plays Role In Emphysema

January 3, 2011 6:33 am | News | Comments

A team of Johns Hopkins Children's Center researchers has discovered that a protein involved in cystic fibrosis (CF) also regulates inflammation and cell death in emphysema and may be responsible for other chronic lung diseases.


BioLineRx BL-5010 Results Positive

January 3, 2011 6:18 am | News | Comments

BioLineRx announces receipt of positive results from the Phase 1/2 clinical trial of BL-5010, a novel formulation for the non-surgical removal of skin lesions.


FDA Approves New Label for INTELENCE

January 3, 2011 6:06 am | News | Comments

The U.S. Food and Drug Administration approved a label update to include a 200 mg formulation of INTELENCE, a non-nucleoside reverse transcriptase inhibitor indicated for the treatment of human immunodeficiency virus in treatment-experienced adults.


Sigma Acquires Cerilliant

January 3, 2011 5:50 am | News | Comments

Sigma-Aldrich Corporation announced it has acquired all outstanding shares of Cerilliant Corporation of Round Rock, Texas to strengthen the company's analytical chemistry product portfolio and to continue to deliver on its strategic growth plans.


FDA Rejects Concentrated Copaxone

January 3, 2011 5:46 am | News | Comments

Teva Pharmaceutical Industries Ltd. said the Food and Drug Administration declined to approve a more concentrated version of its drug Copaxone, a treatment for multiple sclerosis.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.